Abstract
Forty patients who were admitted to hospital with rheumatoid arthritis received a total of 3.9 g/d of enteric-coated acetylsalicylic acid (ASA) (Entrophen) according to one of four dosing schedules: group 1 (n = 13), three 325-mg tablets four times daily; group 2 (n = 11), two 650-mg tablets three times daily; group 3 (n = 10), three 650-mg tablets twice daily; and group 4 (n = 6), two 975-mg tablets twice daily. Five to seven days after the start of therapy, when steady-state plasma salicylate levels had been achieved, 10 blood samples, 1 per hour, were collected. Three healthy volunteers who received plain ASA formed a control group. There was little fluctuation in the salicylate levels over the sampling period, regardless of the dosing interval, and no significant difference in the fluctuations between the five groups. Likewise, there was no significant difference in the mean salicylate levels at each sampling time, regardless of the dosing interval or tablet strength. These results suggest that different tablet strengths of enteric-coated ASA and different dosing intervals produce comparable plasma salicylate levels. Less frequent dosing may improve patient acceptance of salicylate therapy in the treatment of arthritis.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bensen W. G., Laskin C. A., Paton T. W., Little H. A., Fam A. G. Twice-daily dosing of enteric-coated aspirin in patients with rheumatic diseases. J Rheumatol. 1979 May-Jun;6(3):351–359. [PubMed] [Google Scholar]
- Cassell S., Furst D., Dromgoole S., Paulus H. Steady-state serum salicylate levels in hospitalized patients with rheumatoid arthritis. Comparison of two dosage schedules of choline magnesium trisalicylate. Arthritis Rheum. 1979 Apr;22(4):384–388. doi: 10.1002/art.1780220411. [DOI] [PubMed] [Google Scholar]
- Clinite J. C., Kabat H. F. Improving patient compliance. J Am Pharm Assoc. 1976 Feb;16(2):74-6, 85. [PubMed] [Google Scholar]
- Gatley M. S. To be taken as directed. J R Coll Gen Pract. 1968 Jul;16(1):39–44. [PMC free article] [PubMed] [Google Scholar]
- Hulka B. S., Cassel J. C., Kupper L. L., Burdette J. A. Communication, compliance, and concordance between physicians and patients with prescribed medications. Am J Public Health. 1976 Sep;66(9):847–853. doi: 10.2105/ajph.66.9.847. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hussar D. A. Patient noncompliance. J Am Pharm Assoc. 1975 Apr;15(4):183-90, 201. [PubMed] [Google Scholar]
- Lanza F. L., Royer G. L., Jr, Nelson R. S. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med. 1980 Jul 17;303(3):136–138. doi: 10.1056/NEJM198007173030305. [DOI] [PubMed] [Google Scholar]
- Levy G., Giacomini K. M. Rational aspirin dosage regimens. Clin Pharmacol Ther. 1978 Mar;23(3):247–252. doi: 10.1002/cpt1978233247. [DOI] [PubMed] [Google Scholar]
- Levy G., Tsuchiya T. Salicylate accumulation kinetics in man. N Engl J Med. 1972 Aug 31;287(9):430–432. doi: 10.1056/NEJM197208312870903. [DOI] [PubMed] [Google Scholar]
- Mandelli M., Tognoni G. Monitoring plasma concentrations of salicylate. Clin Pharmacokinet. 1980 Sep-Oct;5(5):424–440. doi: 10.2165/00003088-198005050-00002. [DOI] [PubMed] [Google Scholar]
- Orozco-Alcala J. J., Baum J. Regular and enteric coated aspirin: a reevaluation. Arthritis Rheum. 1979 Sep;22(9):1034–1037. doi: 10.1002/art.1780220914. [DOI] [PubMed] [Google Scholar]
- Silvoso G. R., Ivey K. J., Butt J. H., Lockard O. O., Holt S. D., Sisk C., Baskin W. N., Mackercher P. A., Hewett J. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med. 1979 Oct;91(4):517–520. doi: 10.7326/0003-4819-91-4-517. [DOI] [PubMed] [Google Scholar]
- TRINDER P. Rapid determination of salicylate in biological fluids. Biochem J. 1954 Jun;57(2):301–303. doi: 10.1042/bj0570301. [DOI] [PMC free article] [PubMed] [Google Scholar]